Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationReid W. Merryman, Philippe Armand, Arnold S. Freedman et al.|Blood Advances|2022Cited by 19
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with LymphomaReid W. Merryman, Jerome Ritz, Robert Redd et al.|Transplantation and Cellular Therapy|2021Cited by 17
Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell LymphomaReid W. Merryman, Philippe Armand, Robert Redd et al.|Blood|2020Cited by 9
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantationEleanor Taranto, Reid W. Merryman, Robert Redd et al.|Leukemia & lymphoma/Leukemia and lymphoma|2022Cited by 6
Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell TransplantationEleanor Taranto, Reid W. Merryman, Robert Redd et al.|Blood|2021Cited by 1